Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cost of Revenue (2020 - 2025)

Historic Cost of Revenue for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $1.4 million.

  • Insight Molecular Diagnostics' Cost of Revenue rose 3288.59% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 5806.26%. This contributed to the annual value of $3.9 million for FY2024, which is 4110.91% up from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Cost of Revenue of $1.4 million as of Q3 2025, which was up 3288.59% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Cost of Revenue registered a high of $3.3 million during Q4 2021, and its lowest value of $183000.0 during Q2 2022.
  • For the 5-year period, Insight Molecular Diagnostics' Cost of Revenue averaged around $1.4 million, with its median value being $1.0 million (2024).
  • Per our database at Business Quant, Insight Molecular Diagnostics' Cost of Revenue plummeted by 9315.38% in 2022 and then surged by 33989.07% in 2023.
  • Over the past 5 years, Insight Molecular Diagnostics' Cost of Revenue (Quarter) stood at $3.3 million in 2021, then plummeted by 89.91% to $334000.0 in 2022, then soared by 74.25% to $582000.0 in 2023, then soared by 106.53% to $1.2 million in 2024, then rose by 15.31% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $1.5 million for Q2 2025, and $1.2 million during Q1 2025.